Outlook Therapeutics Inc OTLK

US Biotechnology

$0.98 ▼ -6.10% ($-0.06)

🗓️ Earnings Next Week

Open $1.01

Prev Close $1.04

Day Range $0.93 – $1.04

52W Range $0.16 – $3.39

Market Cap $182.62M

Beta 0.76

EPS (TTM) $-1.26

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2016-06-13
Shares Out.	187,000,000
Website	outlooktherapeutics.com/ ↗
Phone	16096193990
Employees	17
Revenue	$127,439
Gross Profit	-$21,888
Net Income	-$4.5M
Total Assets	$21.9M
Total Liabilities	$50.9M
Equity	-$29.0M

About Outlook Therapeutics Inc

Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.

Outlook Therapeutics Inc is a publicly traded company under the ticker symbol OTLK on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.